<DOC>
	<DOCNO>NCT00407979</DOCNO>
	<brief_summary>Cathelicidins small protein human body protect infection . The purpose study determine amount cathelicidins small protein find saliva predict amount skin people acute atopic dermatitis ( AD ) psoriasis .</brief_summary>
	<brief_title>Comparison Cathelicidin Expression Skin Saliva Patients With Atopic Dermatitis Psoriasis</brief_title>
	<detailed_description>People AD psoriasis sensitive skin infection inflammation . A group small proteins known cathelicidins know responsible immune defense infection . People AD psoriasis seem miss protein skin . The purpose study determine amount cathelicidins small protein saliva predictor amount find skin . This single visit observational study . People AD psoriasis , well healthy participant , recruit study . Participants provide detailed medical history undergo physical examination . In addition , saliva blood collection , skin punch biopsy perform .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis typical AD least 6 month define ADVN standardize diagnostic criterion OR diagnosis typical plaque psoriasis least 6 month ADEH participant define ADVN standardize diagnostic criterion Healthy participant personal family history food allergy , AD , asthma , allergic rhinitis Persons reside US Healthy individual systemic disorder outline exclusion criterion Subjects 18 70 year age Male female Exclusion Criteria All Participants : Under 18 70 year age Presence allergic hypersensitivity without stringent AD feature , allow presumptive diagnosis AD Presence AD exfoliative erythroderma Presence psoriasis exfoliative erythroderma presence guttate psoriasis , primary palmoplantar psoriasis , pustular psoriasis Ongoing dental disease ( e.g. , gingivitis ) Bleeding disorder Presence AD psoriasis temporarily stop current medication would cause worsen disease ( Participants active ADEH allow continue medication ) Systemic immunosuppressive chemotherapeutic agent , antiinflammatory biologics ( e.g. , alefacept , etanercept ) , oral calcineurin inhibitor within 30 day screen visit Topical corticosteroid , oral topical antibiotic , oral antiviral , immune enhancer ( e.g. , imiquimod ) , topical calcineurin inhibitor within 7 day prior screen visit ( Participants active ADEH allow continue medication ) Receiving phototherapy ( e.g. , ultraviolet light B [ UVB ] , psoralen plus ultraviolet light A [ PUVA ] ) within 30 day study entry Autoimmune disease immunodeficiency Active fungal , bacterial , viral infection ( Except ADEH subject ) Active systemic cancer . Participants uncomplicated nonmelanoma skin cancer exclude . Mental illness history drug alcohol abuse , opinion investigator , would interfere study Diabetic require medication Pregnancy breastfeed Inability unwillingness participant give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>